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Background
The use of vaccines to prevent and control cholera is currently under debate. Shanchol 
is one of the two oral cholera vaccines prequalified by the World Health Organization; 
however, its effectiveness under field conditions and the protection it confers in the 
first months after administration remain unknown. The main objective of this 
study was to estimate the short-term effectiveness of two doses of Shanchol used 
as a part of the integrated response to a cholera outbreak in Africa.
Methods
We conducted a matched case–control study in Guinea between May 20 and Octo-
ber 19, 2012. Suspected cholera cases were confirmed by means of a rapid test, and 
controls were selected among neighbors of the same age and sex as the case pa-
tients. The odds of vaccination were compared between case patients and controls 
in bivariate and adjusted conditional logistic-regression models. Vaccine effectiveness 
was calculated as (1 − odds ratio) × 100.
Results
Between June 8 and October 19, 2012, we enrolled 40 case patients and 160 controls 
in the study for the primary analysis. After adjustment for potentially confounding 
variables, vaccination with two complete doses was associated with significant 
protection against cholera (effectiveness, 86.6%; 95% confidence interval, 56.7 to 
95.8; P = 0.001).
Conclusions
In this study, Shanchol was effective when used in response to a cholera outbreak 
in Guinea. This study provides evidence supporting the addition of vaccination as 
part of the response to an outbreak. It also supports the ongoing efforts to establish 
a cholera vaccine stockpile for emergency use, which would enhance outbreak preven-
tion and control strategies. (Funded by Médecins sans Frontières.)
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L arge-scale cholera outbreaks have shown the limits of traditional response strategies.1 The devastating consequences 
of cholera epidemics in vulnerable populations 
have opened a debate about ways to improve pre-
paredness and response plans. Two documents, 
issued by the World Health Organization (WHO) 
in 2010 and 2011, have also stimulated debate: 
a revised position paper regarding oral cholera 
vaccines2 and the prequalification of the cholera 
vaccine Shanchol (Shantha Biotech).3
The two oral cholera vaccines currently pre-
qualified by the WHO are killed whole-cell 
Vibrio cholerae serogroup O1 vaccines: Shanchol 
also contains V. cholerae serogroup O139, and 
Dukoral (Crucell) contains a recombinant chol-
era toxin B subunit. Dukoral was shown to pro-
vide 84% protection in the short term (6 months) 
under field conditions and has been used suc-
cessfully in Asia and Africa.4,5 However, the ef-
fectiveness of Shanchol under field conditions 
needs to be determined, because the efficacy of 
the vaccine has been measured only under ex-
perimental conditions in Kolkata, India.6 Further-
more, because that trial was designed to evaluate 
protection in the long term (at 2, 3, and 5 years 
after vaccination), the protection offered by Shan-
chol within the first months after vaccination 
remains unknown.6-8
Shanchol differs from Dukoral in important 
ways: its price is lower ($1.85 vs. $5.25 per dose9), 
it does not require buffer, and its storage volume 
is lower,10 which reduces the logistic burden dur-
ing mass vaccination campaigns. Evidence about 
the protection conferred by Shanchol in the first 
months after administration under field condi-
tions is essential for the consideration of its use 
in an outbreak. This is especially true at a time 
when the WHO and its partners are in the pro-
cess of creating a stockpile of cholera vaccine for 
emergency use.11 In this study, we provide esti-
mates of the effectiveness of Shanchol when used 
in response to an outbreak in an African country.
Me thods
Study Oversight
This study was sponsored by Médecins sans Fron-
tières. The authors assume full responsibility for 
the analyses and interpretation of the data. The 
study protocol was approved by the ethics review 
boards of Guinea and Médecins sans Frontières. 
Vaccine and treatment were provided free of 
charge, and participation in the study was vol-
untary. Written informed consent was obtained 
from participants or their parents or guardians. 
Adverse events were documented by means of 
passive surveillance for 14 days after immuniza-
tion, as described elsewhere.12
Study Setting
The seventh cholera pandemic spread to Guinea in 
1970; the largest outbreak to date was observed in 
1994, with more than 30,000 cases and 670 deaths 
reported nationwide. From 2003 through 2007, 
cholera outbreaks were reported in the capital, 
Conakry, and in the coastal zones during the rainy 
season (July through September). A new cholera 
outbreak was declared in Guinea in February 2012 
(see the Supplementary Appendix, available with 
the full text of this article at NEJM.org). The Na-
tional Microbiology Laboratory in Conakry con-
firmed the circulation of V. cholerae serogroup O1, 
biotype El Tor. Outbreak response interventions 
were implemented, including distribution of free-
of-charge medical treatment, as well as efforts to 
improve access to safe water, improve sanitation, 
and promote hygiene.13-15 In addition, nonselective 
mass vaccination campaigns were implemented in 
the prefectures of Boffa and Forécariah (two doses 
of Shanchol with an interval of at least 2 weeks 
between doses) in accordance with WHO rec-
ommendations.2 In Boffa, residents of the six 
subprefectures bordering the ocean (Koba, Boffa-
Center, Douprou, Tougnifili, and parts of 
Mankountan and Tamita) were vaccinated during 
the period from April 18 to May 14; in Forécariah, 
the residents of the subprefectures of Kaback and 
Kakossa were vaccinated during the period from 
May 27 to June 15 (Fig. S3 in the Supplementary 
Appendix). Details of the vaccination campaigns 
have been published elsewhere.12,16
Surveillance for Cholera
Between April 16 and October 31, 2012, the sur-
veillance system was reinforced in 1 prefectural 
hospital, 8 health centers, and 23 health posts in 
the vaccinated areas. The case definition of sus-
pected cholera (acute, nonbloody, watery diarrhea 
with more than three liquid stools in 24 hours) 
was standardized, and a case-based notification 
system with cholera-specific registers was imple-
mented in collaboration with the African Cholera 
Surveillance Network (Africhol). The medical staff 
was also trained in the use of a rapid diagnostic 
test for cholera (Crystal VC, Span Diagnostics).
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Definition and Selection of Case Patients
All patients with suspected cholera who were 
seeking care in a health center in the study area 
between 1 week after the end of the vaccination 
campaigns and October 31, 2012, were eligible to 
be included as case patients if they provided writ-
ten informed consent and fulfilled the following 
criteria: they had resided in the study area since 
April 16, 2012; they were older than 12 months 
of age; they had a positive result of a rapid diag-
nostic test for cholera; and their residence could 
be located after discharge. Persons with repeated 
episodes of watery diarrhea during the study pe-
riods were included in the study only for the first 
episode.
To assess whether effectiveness estimates could 
be attributed to differences in health-seeking be-
havior between case patients and controls, case 
patients with noncholera diarrhea (i.e., those with 
a negative rapid diagnostic test result) were also 
compared with controls who did not have diarrhea 
(bias-indicator study).4
Definition and Selection of Controls
A neighbor of the same sex and within the same 
age group (1 to 4, 5 to 9, 10 to 19, 20 to 29, 30 to 
39, or 40 years of age or older) as the case patient 
was eligible to be a control if he or she had not 
sought treatment for diarrhea between January 1, 
2012, and the date of onset of the matched case 
patient’s diarrheal illness and if he or she would 
have sought treatment in a health center if severe, 
watery diarrhea had developed. Eligible controls 
were also required to meet the same informed 
consent and residency and age criteria that were 
used to select the case patients.
Four neighbor controls were selected for each 
case patient and were included in the primary 
analysis and the bias-indicator analysis (Fig. 1). 
Beginning with the first household to the left of 
the case patient’s residence and using a sampling 
interval of three households, we recruited one con-
trol per household until four had been recruited.
Ascertainment of Vaccination  
and Potentially Confounding Variables
Receipt of the cholera vaccine during the mass 
immunization program was ascertained in face-
to-face home interviews. Participants were asked 
whether they had been vaccinated and, if so, to 
show the vaccination cards. For those who re-
ported that they had been vaccinated but were 
not in possession of a card, vaccination status 
and the completeness of dose ingestion were re-
corded as orally reported by the participant. Clin-
ical, demographic, socioeconomic, and environ-
mental variables were ascertained with the use of 
questionnaires.
Laboratory Procedures
For each case patient included in the study, a 
stool sample was collected and used to perform 
the rapid diagnostic test. The doctor or nurse in 
charge of the health center performed the test 
and interpreted the result in accordance with the 
manufacturer’s instructions.
In addition, for patients with a positive rapid 
diagnostic test result, a filter-paper disk was 
dipped into fresh stool and placed in a micro-
tube with two or three drops of normal saline 
solution (0.9% sodium chloride). Tubes were stored 
at room temperature and sent to Institut Pasteur 
(Paris) for isolation of V. cholerae with the use of 
standard methods.17 A polymerase chain-reaction 
(PCR) assay was systematically performed on all 
specimens. Detection of the rfb gene for the iden-
tification of V. cholerae was performed as described 
by Hoshino et al.18 PCR amplification of an exog-
enous internal positive control (TaqMan, Applied 
Biosystems) incorporated into each sample and 
amplification of the 16S ribosomal RNA (rRNA) 
gene were used to control for PCR inhibitors and 
bacterial DNA, respectively.
Statistical Analysis
In the primary analysis, we assessed the protec-
tion conferred by two completely ingested doses 
of vaccine against cholera confirmed by rapid di-
agnostic testing. Assuming 50% vaccine effec-
tiveness, we calculated that we would need to 
include 90 case patients and 360 controls (ratio, 
1:4) for the study to have 80% power at an alpha 
error of 5%. In the secondary analysis, we as-
sessed the protection conferred by an incomplete 
course of vaccination (one complete dose, or one 
or two doses that were incomplete because the 
patient spat out the dose or vomited). We also 
conducted a subanalysis in which case patients 
were considered to be those in whom the pres-
ence of V. cholerae was confirmed by culture, PCR, 
or both, as well as a bias-indicator analysis in 
which case patients were considered to be those 
who had diarrhea but with a negative result of 
rapid diagnostic testing.
We compared the odds of vaccination be-
tween case patients and controls through condi-
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tional logistic regression to account for the 
matching design; we fit a model with indicator 
variables for nonvaccinated participants and par-
ticipants who received incomplete or complete 
doses of vaccine. We calculated the level of vac-
cine protection as (1 − odds ratio) × 100.
We compared demographic, environmental, 
and socioeconomic factors between case pa-
tients and matched controls to assess their po-
tential as confounders of vaccine protection. We 
considered as possible confounders variables for 
which P values were less than 0.20 in the bivari-
ate models. We obtained an adjusted estimate of 
vaccine protection by adjusting for covariables 
that significantly improved the likelihood of the 
model. All reported P values and 95% confi-
dence intervals are two-sided. A P value of less 
than 0.05 was considered to indicate statistical 
significance. Stata/SE, version 10 (StataCorp), 
was used for analyses.
R esult s
Baseline Characteristics
From May 21 to October 31, 2012, a total of 
239 patients with acute, nonbloody diarrhea were 
treated at health centers in the study area, 5 of 
whom died (case fatality rate, 2%); 40 of the 
239 patients and 160 controls were enrolled in 
the primary analysis between June 8 and October 
19, 2012 (Fig. 1 and 2). None of the case patients 
enrolled in the study died. The median age of the 
83 Fulfilled the inclusion criteria
239 Patients with acute watery diarrhea
were assessed for eligibility
156 Were excluded
73 Resided outside the study area
24 Moved into the study area after
the vaccination campaign
2 Died before biologic confirmation
2 Did not have liquid stools after
enrollment
48 Did not have RDT performed
2 Had invalid RDT result owing to
absence of control line
5 Were lost to follow-up
40 Had positive RDT results
(primary analysis)
43 Had negative RDT results
(bias-indicator analysis)
4 Did not undergo
culture and PCR testing
172 Matched
controls
160 Matched
controls
18 Had positive results of culture, 
PCR, or both
13 Had positive culture and
and PCR results
5 Had negative culture results
and positive PCR results
18 Had positive culture results
and negative PCR results
Figure 1. Enrollment of Study Participants for the Primary Analysis and Subanalyses.
Four matched controls were selected for each case patient. Of the 40 patients with positive results of a rapid diagnostic test 
(RDT), 4 did not undergo culture testing and polymerase-chain-reaction (PCR) testing because filter paper was not available.
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study participants was 28.0 years (interquartile 
range, 16.5 to 39.0); 35% of the participants were 
female (Table 1). Half the case patients sought 
care on the day of symptom onset. At the time of 
admission, 70% of the case patients were dehy-
drated.
Of 36 case patients included in the primary 
analysis for whom a specimen was sent for culture 
and PCR analysis, 18 (50%) were positive for 
V. cholerae serogroup O1 biotype El Tor, serotype 
Ogawa; 13 had positive results of culture and PCR, 
and 5 had positive PCR results but negative culture 
results. Samples from all 36 case patients showed 
a weak amplification signal for the 16S rRNA 
gene. Among the 18 negative specimens, 5 had an 
almost undetectable amplification signal.
In addition, 43 case patients with watery diar-
rhea and a negative rapid diagnostic test result and 
172 controls were recruited for the bias-indicator 
analysis (Fig. 1 and 2).
Analysis of Confounders and Effect Modifiers
Case patients with cholera confirmed by rapid 
diagnostic testing were more likely than controls 
to have eaten in public places and to have shared 
a latrine with persons who had cholera (Table 1, 
and Table S1 in the Supplementary Appendix). 
The baseline characteristics of the case patients 
without cholera and the matched controls includ-
ed in the bias-indicator analysis are shown in 
Table S2 in the Supplementary Appendix.
Vaccine Effectiveness
In the crude analysis and after adjustment for 
potential confounders, vaccination with two 
complete doses was associated with significant 
protection against cholera (adjusted effective-
ness, 86.6%; 95% confidence interval [CI], 56.7 
to 95.8; P = 0.001) (Table 2). The estimate of the 
effectiveness of an incomplete course of vaccine 
was not precise enough to be conclusive (42.8%; 
95% CI, −83.6 to 82.2; P = 0.35).
In the subanalysis that included only case 
patients with cholera confirmed by culture, PCR, 
or both, vaccination with two complete doses 
was also associated with significant protection 
against cholera (91.6%; 95% CI, 58.6 to 98.3; 
P = 0.002) (Table 3). The odds of vaccination did 
not differ significantly between patients with 
watery diarrhea not caused by cholera and con-
trols, suggesting the absence of bias in the 
primary analysis (Table 3).
Discussion
Our results show the effectiveness of two com-
plete doses of Shanchol administered as part of 
the response to a cholera epidemic in Africa. Our 
estimate of the short-term protection conferred 
by Shanchol is in line with previous results for 
Dukoral.4 This is relevant in light of the low lev-
els of protection provided by oral vaccines in low-
income African settings in the past.19-21
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Figure 2. Cases of Acute Diarrhea Reported in the Study Areas.
Cases reported after the starting date of the study (circled in red; week 20 
of the calendar year in the Boffa prefecture and week 24 in the Forécariah 
prefecture) are shown. The cholera cases confirmed by RDT and included 
in the primary analysis are shown in red, the noncholera cases (RDT-nega-
tive) included in the bias-indicator analysis are shown in yellow, and sus-
pected cholera cases not included in the analysis are shown in gray.
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This study was performed under field condi-
tions during a cholera outbreak and therefore 
has several limitations. The immunization cam-
paign in response to the outbreak was part of 
the control strategy implemented by the Guinea 
Ministry of Health with the support of Médecins 
sans Frontières; thus, exposure to the vaccine 
in the population was not controlled. Overall, 
316,250 vaccines were delivered, and 48 patients 
reported nonsevere adverse events after immuni-
zation (Table S4 in the Supplementary Appen-
dix); the vaccine coverage ranged from 69% in 
the Koba subprefecture to 84% in the Mankoun-
tan subprefecture.12 High vaccination coverage 
reduces transmission in vaccinated communities 
(herd protection),22-24 thereby directly and indi-
rectly reducing the risk of cholera. In the past, 
this has limited opportunities to measure vaccine 
effectiveness25 because of difficulties in recruit-
ing case patients. In our study, most of the case 
patients were recruited from Koba (in the Boffa 
prefecture), where a small local outbreak was 
reported (August through October 2012). Koba 
had the lowest vaccination coverage in the study 
area,12 and it borders Dubreka, where high 
transmission was reported (overall attack rate, 
17 cases per 10,000 population) (see the Supple-
mentary Appendix). Although the sample was 
small, the power was high (99%), because the 
observed vaccine effectiveness was higher than 
the value assumed for the calculation of sample 
size. However, the small sample limited the pos-
sibility of conducting analyses stratified by age 
and of estimating the effectiveness of a single 
dose with sufficient precision. This latter esti-
mate of effectiveness, although not significant, 
Table 1. Characteristics of Case Patients and Controls.*
Characteristic
Controls 
(N = 160)
Case Patients 
(N = 40) P Value
Female sex — no. (%) 56 (35) 14 (35)
Age — yr
Median 28 28
Interquartile range 16–39 18–36
Occupation — no. (%) 0.18
Trader 29 (18) 8 (20)
Farmer 37 (23) 16 (40)
Student 29 (18) 3 (8)
Fisherman 10 (6) 3 (8)
Housewife 10 (6) 1 (3)
Unemployed 22 (14) 6 (15)
Other 23 (14) 3 (8)
Educational level and literacy of head of household — no./total no. (%) 0.13
None 43/158 (27) 13/40 (33)
Primary school 5/158 (3) 4/40 (10)
Secondary school 21/158 (13) 2/40 (5)
University 5/158 (3) 0
Literate 84/158 (53) 21/40 (53)
Has telephone in home — no. (%) 128 (80) 27 (68) 0.10
Household size — no. (%) 0.06
0–4 members 34 (21) 17 (43)
5–7 members 40 (25) 7 (18)
8–12 members 49 (31) 9 (23)
>12 members 37 (23) 7 (18)
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was substantially lower than that for two doses, 
and the point estimate was in line with previous 
findings with other oral cholera vaccines.4,6,24
Despite the wide and systematic distribution 
of vaccination cards and the short time span 
between the vaccination campaign and the data 
collection, 25% of the vaccinated people inter-
viewed were not able to provide their vaccination 
card at the time of the study. Because we were 
not able to confirm vaccination status for all 
participants, some information bias may be pres-
ent. Nevertheless, even if we consider the worst-
case scenario, in which all the participants who 
were unable to find their vaccination card were 
not vaccinated, the vaccine effectiveness would 
still reach 82% (see the Supplementary Appendix).
Case–control studies of vaccine effectiveness 
may also be prone to bias related to differences 
in health-seeking behavior. To measure this po-
tential bias, we conducted a supplementary, bias-
indicator analysis, comparing the odds of vacci-
nation among patients with watery diarrhea not 
caused by cholera and a sample of matched 
controls. The odds of vaccination did not differ 
significantly between these two groups, and we 
interpret this finding as indicating the absence 
of a large bias in health-seeking behavior.
Despite the difficulties inherent in assessing 
vaccine effectiveness under field conditions, we 
were able to provide estimates of the short-term 
protection (during the first 6 months) conferred 
by Shanchol in Africa, where the effect of the 
Table 1. (Continued.)
Characteristic
Controls  
(N = 160)
Case Patients 
(N = 40) P Value
Proportion of children in the household attending school  
— no./total no. (%)
0.13
None 33/144 (23) 14/37 (38)
Less than half 42/144 (29) 11/37 (30)
Half or more 51/144 (35) 8/37 (22)
All 18/144 (13) 4/37 (11)
Distance to the closest health center — no. (%) 0.10
Transportation required 107 (67) 31 (78)
Walking distance 53 (33) 9 (23)
Lives in household with one or more other persons with cholera 
— no./total no. (%)
4/159 (3) 3/40 (8) 0.15
Drinking water treated in the previous week — no. (%)† 0.15
No 26 (16) 11 (28)
At least 1 day 34 (21) 5 (13)
Every day 100 (63) 24 (60)
Ate food in a public place in the previous week — no./total no. (%) 0.02
Never 72/160 (45) 11/39 (28)
At least 1 day 49/160 (31) 20/39 (51)
Every day 39/160 (24) 8/39 (21)
Usual place of defecation — no. (%) 0.12
Latrine 81 (51) 17 (43)
Pit in the yard 56 (35) 14 (35)
On the ground 23 (14) 9 (23)
Shares a latrine with someone who has cholera — no./total no. (%) 5/136 (4) 6/30 (20) 0.001
* Percentages may not sum to 100 because of rounding.
† Water was treated with chlorine or was boiled before consumption.
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oral cholera vaccine is expected to be the highest 
in reducing mortality1,26 and where problems with 
the protection provided by oral vaccines have been 
documented in the past.21 The crude and adjusted 
estimates of effectiveness were similar after the 
effect of a large number of well-described pos-
sible confounders was explored, as well as when 
only cases confirmed by PCR or culture were 
considered. The low proportion of PCR-positive 
samples could be related to the small amount or 
the poor quality of biologic material, as indi-
cated by the weak amplification signal of the 
16S rRNA gene. False positive rapid diagnostic 
test results cannot be ruled out27,28; however, 
this nondifferential misclassification would have 
underestimated vaccine effectiveness.
The results presented here suggest that the 
protection conferred by Shanchol may be higher in 
the first 6 months than in the remaining 2 years 
after vaccination (an estimate of 67% was re-
ported by Sur et al. for the 2-year period after 
vaccination6), probably as a result of waning im-
munity. This difference may also be explained in 
part by the possibility that some nonvaccinated 
Table 2. Effectiveness of Complete and Incomplete Vaccination.
Vaccination Status
Controls 
(N = 160)
Case 
Patients 
(N = 40)
Crude Estimate  
of Vaccine 
Effectiveness* P Value
Adjusted Estimate 
of Vaccine 
Effectiveness† P Value
no. of patients (%) % (95% CI) % (95% CI)
No vaccination 23 (14) 15 (38) Reference Reference
Incomplete vaccination‡ 36 (23) 14 (35) 38.9 (−55.2 to 76.0) 0.30 42.8 (−83.6 to 82.2) 0.35
Full vaccination 101 (63) 11 (28) 84.0 (59.7 to 93.6) <0.001 86.6 (56.7 to 95.8) 0.001
* Vaccine effectiveness was based on the odds of vaccination among case patients and controls; crude vaccine effective-
ness was calculated as (1 − odds ratio) × 100.
† Estimates were adjusted according to the number of people living in the household, whether drinking water was treat-
ed, and whether a latrine was shared with a person who had cholera.
‡ Vaccination was considered incomplete if only one dose was taken or if one or both doses were spat out or vomited.
Table 3. Vaccine Effectiveness in the Subanalyses.*
Subanalysis Controls Case Patients
Crude Estimate of  
Vaccine Effectiveness P Value
no./total no. (%) % (95% CI)
Culture–PCR assay subanalysis†
No vaccination 10/72 (14) 8/18 (44) Reference
Incomplete vaccination 17/72 (24) 6/18 (33) 66.2 (−53.0 to 92.6) 0.16
Full vaccination 45/72 (63) 4/18 (22) 91.6 (58.6 to 98.3) 0.002
Controls
Patients with Diarrhea 
Not Due to Cholera
Crude Estimate of  
Vaccine Effectiveness P Value
no./total no. (%) % (95% CI)
Bias-indicator subanalysis‡
No vaccination 9/172 (5) 4/43 (9) Reference
Incomplete vaccination 35/172 (20) 7/43 (16) 48.1 (−177.1 to 90.3) 0.44
Full vaccination 128/172 (74) 32/43 (74) 25.2 (−225.2 to 82.8) 0.70
† Only patients with cholera confirmed by culture, polymerase-chain-reaction (PCR) assay, or both were included in this 
subanalysis.
‡ In this subanalysis, patients with diarrhea that was not due to cholera (as indicated by negative results of a rapid diag-
nostic test) were compared with controls who did not have diarrhea, in an attempt to assess whether the results with 
respect to effectiveness could be attributed to differences in health-seeking behavior between case patients and controls.
The New England Journal of Medicine 
Downloaded from nejm.org on June 3, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Use of Vibrio choler ae Vaccine in an Outbreak
n engl j med 370;22 nejm.org may 29, 2014 2119
participants in the study by Sur et al. had natu-
rally acquired immunity because cholera is en-
demic in Kolkata. In addition, our estimate 
might reflect some indirect protection, although 
indirect effects were minimized through the 
matched design.22,23
A factor that does not seem to have reduced 
the short-term protection provided by Shanchol 
is the cold-chain strategy used in Guinea, where 
vaccines were stored under cold chain but were 
transported and used at ambient temperature on 
the day of vaccination. The vial temperature 
monitor of each vaccine was checked for stabil-
ity before administration, and all monitors indi-
cated that the vaccines remained valid for use. 
These results are not surprising, in light of the 
good heat stability of Dukoral,29 but more robust 
documentation is required to allow for more 
flexible delivery strategies in the future. The use 
of oral cholera vaccine in outbreak contexts 
could also be substantially simplified if it were 
effective as a single-dose regimen. Our study 
was underpowered to provide precise estimates 
of the protection provided by a single dose of 
vaccine. Determining the short-term protection 
provided by one dose is a clear priority for the 
implementation of efficient and timely vaccina-
tion campaigns in response to cholera outbreaks.
In conclusion, our estimates of the short-
term effectiveness of Shanchol provide essen-
tial information regarding the rapid use of oral 
cholera vaccine to improve the current strate-
gies for outbreak prevention and control. This 
evidence should serve to support the addition 
of oral cholera vaccines to the tools used in 
responses to epidemics.
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